What the hell is going on with the Oxford-AstraZeneca vaccine?

The problem child of COVID-19 vaccines was back in the news this week. After South Africa suspended the Oxford-AstraZeneca vaccine’s use when it failed to slow the spread of the predominant B.1.351 variant, vaccination using this vaccine has been suspended and then resumed in many European countries following reports of blood clots in some people who received it. 

According to a release from AstraZeneca, there have been 15 cases of deep vein thrombosis and 22 cases of pulmonary embolism in people who have gotten the vaccine, as of March 8. These are serious complications—seven of those people died. Countries that suspended the vaccine’s use include Spain, Italy, France, and Germany, among others. (Europe tends to act as more of a bloc than North America when it comes to vaccines. Consider: Canada has authorized use of the AstraZeneca vaccine while the US has literal fridges full of the stuff just sitting there waiting for approval.)

Since the initial suspension, investigations have been launched and apparently concluded that there is no causative relationship between the vaccine and these symptoms. According to Emer Cooke, the executive director of the European Medicines Agency (EMA), in a press conference on March 18: “The committee… concluded that the vaccine is not associated with an increase in the overall risk of thromboembolic events or blood clots.”

And, according to the WHO on March 17: “At this time, WHO considers that the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.” Europe has since started to resume vaccinating with the Oxford-AstraZeneca vaccine, starting with France, Germany, and Italy. (Except not in Finland, where they just suspended it again after two people got similar blood clots.)

So all’s well that ends well right? Well, not necessarily. Besides that Finland wrinkle, some scientists and officials are concerned that this entire rigmarole could undermine public trust in the AstraZeneca vaccine. It’s worth noting that a tiny population experienced these effects out of the millions of people who have already gotten the vaccine. And blood clots are fairly common in the population; you’re going to expect some people to develop them just by sheer chance. But it’s also worth noting that these complications are serious, and rare among the age group that they were reported in. Not slowing down could have the same fear-inducing effect. As Shobita Parthasarathy says in her Slate column, “[T]his crisis isn’t about science at all. It’s about public trust, and scared citizens cannot be easily convinced by expertise that feels remote. Our solutions need to reflect that.”

We’ll see if anything else happens. But in the meantime, the US has since promised to share its stockpile of the Oxford-AstraZeneca vaccine with Canada and Mexico, so it looks like it’s at least medium-steam ahead for now. 

In summation:

More vaccine posts

  • The booster shot conversation: What you should know
    Recently, a lot of U.S. COVID-19 news has centered around booster shots—additional vaccine doses to boost patients’ immunity against the coronavirus. Questions abound: do we need these shots, when might we need them, how do they impact vaccination campaigns?
  • What’s up with Texas’ county-level vaccination data?
    Anyone who’s tried to work with the federal government’s vaccination data has noticed this issue: there’s a Texas-shaped hole in the numbers. While the CDC and HHS report vaccination data for counties and metropolitan areas in the vast majority of states, data are missing for the entire state of Texas.
  • Breakthrough cases: What we know right now
    While epidemiologists may consider any new outbreak a possible source of new variants, one key way to monitor the virus/variant race is by analyzing breakthrough cases—those infections that occur after someone has been fully vaccinated. Here’s how states and the CDC are tracking these cases now, and what we know about vaccine protection against the variants.
  • The US missed Biden’s July 4 goal: How did your community do?
    The U.S. missed President Biden’s big vaccination goal: 70% of adults vaccinated with at least one dose by July 4. As of July 3, we are at 67% of adults with one dose, and 58% fully vaccinated. But rates vary widely by state and county: There are over 1,000 counties in the U.S. with one-dose vaccination rates under 30%, CDC Director Dr. Walensky said at a press briefing last week.

2 thoughts on “What the hell is going on with the Oxford-AstraZeneca vaccine?

Leave a Reply